Zinc 2-aminobutanedioate--aspartic acid (1/1/1)
CAS 36393-20-1
Zinc 2-aminobutanedioate--aspartic acid (1/1/1) (CAS 36393-20-1) is a pharmaceutical compound with 0 bioactivity targets and 34 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Cross-Reference to Chemicals
Same-CAS substance identity is available in the industrial chemicals vertical.
Zinc 2-aminobutanedioate--aspartic acid (1/1/1) is linked to DTXSID30957730 in DSSTox identifiers.
View industrial chemical data →Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Zinc 2-aminobutanedioate--aspartic acid (1/1/1) used for in pharmaceutical contexts?
Zinc 2-aminobutanedioate--aspartic acid (1/1/1) (CAS 36393-20-1) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Zinc 2-aminobutanedioate--aspartic acid (1/1/1)?
Zinc 2-aminobutanedioate--aspartic acid (1/1/1) has 34 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Aggression, Agitation, Angular cheilitis, Blepharospasm, Crohn's disease. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Zinc 2-aminobutanedioate--aspartic acid (1/1/1) also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for ZINC ASPARTATE with EU status "restricted".
What clinical phase is Zinc 2-aminobutanedioate--aspartic acid (1/1/1) in?
No phase 1-4 clinical development badge is rendered for Zinc 2-aminobutanedioate--aspartic acid (1/1/1) because the matched compound identifier rows do not contain a max-phase value.